TITLE:
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva

CONDITION:
Post-Menopausal Osteoporosis

INTERVENTION:
ibandronate [Bonviva/Boniva]

SUMMARY:

      This 2 arm study will assess the long-term efficacy and safety of oral treatment with 100mg
      or 150mg Bonviva in women with post-menopausal osteoporosis who have previously completed
      Bonviva study BM16549 (MOBILE study). Patients will receive Bonviva either 100mg po monthly,
      or 150mg po monthly. Patients will also receive daily supplementation with vitamin D and
      calcium. The anticipated time of study treatment is 2+ years, and the target sample size is
      500+ individuals.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: N/A to N/A
Criteria:

        Inclusion Criteria:

          -  successful completion of Bonviva study BM16549, with at least 75% compliance;

          -  ambulatory.

        Exclusion Criteria:

          -  malignant disease diagnosed within the previous 12 years (except basal cell cancer
             that has been successfully removed);

          -  breast cancer diagnosed within the previous 22 years.
      
